Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. - Wikidata - awgldk - TriplyDB

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.

http://www.wikidata.org/entity/Q34585578

about

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Bispecific T-cell engagers for cancer immunotherapy.Are BiTEs the "missing link" in cancer therapy?The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.Cancer therapy with bispecific antibodies: Clinical experience.Bispecific antibodies engage T cells for antitumor immunotherapy.T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell Toxicity management for patients receiving novel T-cell engaging therapies.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110 T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6 Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia Targeting T cells with bispecific antibodies for cancer therapy Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.Investigational immunotherapeutics for B-cell malignancies.Bispecific antibodies for cancer therapy.New antibody drug treatments for lymphoma.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Antibody therapy for acute lymphoblastic leukemia.Current status of antibody therapy in ALL.Blinatumomab for the treatment of B-cell lymphoma.Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

P2860

Q24644083-B6339DBE-E16F-4500-B680-88E796D336ED Q26785828-2A2D2D99-4FDB-461D-A5D3-20E69B46C999 Q27313856-C75359E4-A624-4BF6-A25E-61C1475188B4 Q27693313-98D598A8-B09B-48DC-88C3-70968B789DC4 Q28083907-46B88DE2-103D-44EB-B49F-7F7554E4E28B Q28730117-6800DD45-2D0A-42C1-A202-07A8E8B5CD2E Q33665884-CCCF46DE-8B2E-4DC8-880A-9039B746273C Q34005156-17A2A58A-0FE8-477A-A6B3-1D9C99CFF109 Q34118856-2EFC676B-746F-4B24-8FC3-412575973A45 Q34174334-46938AB6-B909-4062-99A1-D22DD3C5C9CA Q34227769-4CDB4B99-055C-4B21-9907-00425E4FA108 Q34343346-1C87FF08-D204-4205-A7FE-72834AB7AAC4 Q34517676-D2D03D0B-FFFD-4BE7-863B-5AF4B1A2DB95 Q34570056-EAE224B4-60CE-4D49-99D7-75ACB802CC26 Q35152029-6B753847-4A13-45EF-8843-1DFA631443AE Q35368001-FE938EBB-9ECD-49B7-A679-624D6F158B9E Q35808466-31839C8A-CA95-4A88-8ED2-C2329B330794 Q35824663-E21E0ABF-A774-4231-B32B-D3CB655FA7CF Q36022539-B782C457-26AD-4518-BF16-DF67A86305A4 Q36211422-4B014A53-7AF9-49A7-AFAC-D4B6800D999B Q36821083-B852E7E3-359B-4DD6-A7D3-66BC3E627CAD Q36834079-D8D6607F-76B0-4AD6-ACBB-24B2034B3AE8 Q37220742-F58149E6-93B5-4859-B765-B85F81AA615D Q37376659-254F2EA7-F0CA-40A6-BB9C-F9DDE208ACCA Q37667386-E845ACF5-426C-4B9D-891D-9865BE965890 Q37773263-A5ECC259-F5CE-47D3-9749-3ADFD7105BC6 Q37852003-9AB78850-F7D3-4B5F-A222-4CC7CCB139BA Q37913356-BBC0F67C-ACD1-4C77-93D9-D957A55BB50B Q37994136-964F7D42-E5CA-4171-AB4B-E27FED1462B7 Q38266338-7556164D-4E60-4C53-A0C5-79E06DD9FF12 Q38367679-445BF808-40F5-4B2C-9207-3FBF6EAD88E0 Q38707896-DB32B2B4-2A4E-49C6-816B-1652EED2EA45 Q38728592-2CD262BF-CCBA-4DD5-8CD8-ABBA4EA87C79 Q38808823-48743A41-8BDC-4ABA-B7B3-F63E03DC5893 Q39044411-42283239-388C-496E-9DE2-EE433932EA6B Q39128240-B30E9B36-F790-4112-A5A8-1DBD4893FF01 Q39323781-86D1C305-B746-46A8-837E-A184F4CB140C Q39733328-E632C1EC-1238-444C-BABC-E1688404B6B9 Q40043393-D9EF72F1-9753-4C44-8222-F1F94464D9AF Q40152125-3AE58C1F-8BEA-481A-8D1D-0CEF6191EFE4

P2860

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.

http://www.wikidata.org/entity/Q34585578

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Strictly target cell-dependent ...... constructs of the BiTE class.

@ast

Strictly target cell-dependent ...... constructs of the BiTE class.

@en

Strictly target cell-dependent ...... constructs of the BiTE class.

@nl

type

label

Strictly target cell-dependent ...... constructs of the BiTE class.

@ast

Strictly target cell-dependent ...... constructs of the BiTE class.

@en

Strictly target cell-dependent ...... constructs of the BiTE class.

@nl

prefLabel

Strictly target cell-dependent ...... constructs of the BiTE class.

@ast

Strictly target cell-dependent ...... constructs of the BiTE class.

@en

Strictly target cell-dependent ...... constructs of the BiTE class.

@nl

P1433

Q34585578-EA42B32C-9908-435E-9287-6CCE2A4BFAD2

P1476

Q34585578-9918979F-C0DD-49CE-ABAB-94F88FE1D67E

P2093

Q34585578-56A9DDD8-AC81-451D-BE75-55FBBFCFA3B1

Q34585578-6BBD9916-A66A-46EC-A426-7306CDF64476

Q34585578-73FF4F0B-9BE4-484E-A607-4A1A5FDEA2B5

Q34585578-85221D78-8E43-4E3A-8139-F2441A83CE54

Q34585578-8A03D8CF-04A9-4BE3-8020-6EE7A3741B6C

Q34585578-9241D20E-3F80-4260-AA00-6BB8BC02D39D

Q34585578-A33D4177-1ABA-40F4-B773-8613358E807D

Q34585578-B4454992-7D81-4786-AD52-F22B5D4B7762

Q34585578-C0ECDE11-A33A-4762-B74C-83A4F859C168

Q34585578-D11D4A18-192F-4294-AA87-C5A1582EA861

P304

Q34585578-35A900F3-1291-4FCE-8B1D-F30F30F033A5

P31

Q34585578-CDDD6D1B-67E3-43A6-9D54-E19264E0E88B

P356

Q34585578-2909E502-E56D-41F9-8560-F7F9BA2A9546

P433

Q34585578-F043DF41-64D4-4A18-937A-F7EB3CE33231

P478

Q34585578-C7A2FF75-6710-42F7-9DEE-CC67CDB444B6

P577

Q34585578-FA1DF9CD-B25C-469A-9EAB-1379E1D97D47

P698

Q34585578-8B2000DB-5F27-4A14-AF08-FE5D97DF206D

P921

Q34585578-82A49E98-EA78-4FFA-9DD2-25227E1ABD6F

P356

CJI.0B013E318156750C

P1433

Journal of Immunotherapy

P1476

Strictly target cell-dependent ...... constructs of the BiTE class.

@en

P2093

Bernd Schlereth

http://www.w3.org/2001/XMLSchema#string

John Lumsden

http://www.w3.org/2001/XMLSchema#string

Jörg Volkland

http://www.w3.org/2001/XMLSchema#string

Klaus Brischwein

http://www.w3.org/2001/XMLSchema#string

Larissa Parr

http://www.w3.org/2001/XMLSchema#string

Mathias Locher

http://www.w3.org/2001/XMLSchema#string

Matthias Klinger

http://www.w3.org/2001/XMLSchema#string

Patrick A Baeuerle

http://www.w3.org/2001/XMLSchema#string

Peter Kiener

http://www.w3.org/2001/XMLSchema#string

Peter Kufer

http://www.w3.org/2001/XMLSchema#string

P304

798-807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CJI.0B013E318156750C

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18049331

http://www.w3.org/2001/XMLSchema#string

P921